Tonix Pharmaceuticals Holding (Nasdaq:TNXP) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

TNXP Overzicht aandelen

TNXP fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 51.46% per year

Trading at good value compared to peers and industry

Risicoanalyse

Highly volatile share price over the past 3 months

Does not have a meaningful market cap ($3M)

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Tonix Pharmaceuticals Holding Corp. Concurrenten

Gamida Cell

OTCPK:GMDA.Q

US$2.6m

Eterna Therapeutics

NasdaqCM:ERNA

US$5.7m

Scinai Immunotherapeutics

NasdaqCM:SCNI

US$2.9m

Onconetix

NasdaqCM:ONCO

US$43.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Tonix Pharmaceuticals Holding
Historische aandelenkoersen
Huidige aandelenkoers	US$0.14
52 Week Hoogtepunt	US$22.14
52 Week Laag	US$0.13
Bèta	2.1
11 maand verandering	-40.83%
3 maanden verandering	-84.84%
1 Jaar Verandering	-99.21%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	TNXP	US Biotechs	US Markt
7D	4.2%	-0.2%	-0.4%
1Y	-99.2%	22.1%	34.1%

Rendement versus industrie: TNXP underperformed the US Biotechs industry which returned 21.7% over the past year.

Rendement versus markt: TNXP underperformed the US Market which returned 33.4% over the past year.

Prijsvolatiliteit

Is TNXP's price volatile compared to industry and market?
TNXP volatility
TNXP Average Weekly Movement	17.2%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: TNXP's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: TNXP's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	103	Seth Lederman	www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp., een biofarmaceutisch bedrijf, richt zich op het ontwikkelen, ontdekken, commercialiseren en in licentie geven van therapeutica voor het behandelen en voorkomen van menselijke ziekten en het verlichten van lijden. Het brengt Zembrace SymTouch en Tosymra op de markt voor de behandeling van acute migraine met of zonder aura bij volwassenen. De portefeuille richt zich op aandoeningen van het centrale zenuwstelsel en op kandidaat-geneesmiddelen voor zeldzame ziekten, immunologie en infectieziekten.

Tonix Pharmaceuticals Holding Corp. Samenvatting

Hoe verhouden de winst en inkomsten van Tonix Pharmaceuticals Holding zich tot de beurswaarde?
TNXP fundamentele statistieken
Marktkapitalisatie	US$3.27m
Inkomsten(TTM)	-US$149.01m
Inkomsten(TTM)	US$12.46m

0.2x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is TNXP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TNXP resultatenrekening (TTM)
Inkomsten	US$12.46m
Kosten van inkomsten	US$9.77m
Brutowinst	US$2.69m
Overige uitgaven	US$151.70m
Inkomsten	-US$149.01m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-6.77
Brutomarge	21.59%
Nettowinstmarge	-1,196.11%
Schuld/Eigen Vermogen Verhouding	20.2%

Hoe presteerde TNXP op de lange termijn?

Bekijk historische prestaties en vergelijking

TNXP Overzicht aandelen

Beloningen

Risicoanalyse

Tonix Pharmaceuticals Holding Corp. Concurrenten

OTCPK:GMDA.Q

US$2.6m

NasdaqCM:ERNA

US$5.7m

NasdaqCM:SCNI

US$2.9m

NasdaqCM:ONCO

US$43.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Tonix Pharmaceuticals Holding Corp. Announces its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

Tonix Pharmaceuticals Presents Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Vaccine

Tonix Pharmaceuticals Holding Corp Announces the Appointment of Thomas Englese as Executive Vice President of Commercial Operations

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $10 million worth of its shares.

Tonix Pharmaceuticals Holding Corp. Presents Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium

Recent updates

Tonix Pharmaceuticals Holding Corp. Announces its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

Tonix Pharmaceuticals Presents Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Vaccine

Tonix Pharmaceuticals Holding Corp Announces the Appointment of Thomas Englese as Executive Vice President of Commercial Operations

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $10 million worth of its shares.

Tonix Pharmaceuticals Holding Corp. Presents Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium

Tonix Pharmaceuticals Holding Corp. Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication

Tonix Pharmaceuticals Holding Corp. Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, Tnx-801, as Who Declares Mpox Outbreak A Global Health Emergency

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain

Tonix Pharmaceuticals Holding Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. Announces Potential Positive Impact of U.S. National Academies New Definition of Long COVID on Size of Fibromyalgia Market for Tonmya

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $50 million.

Tonix Pharmaceuticals Holding Corp. Grants Fast Track Designation by FDA for Tonmya for Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Set to File an NDA for Tonmya for the Management of Fibromyalgia, Is Planning Expected Launch in 2H 2025

Tonix Pharmaceuticals Holding Corp. announced that it expects to receive $30 million in funding

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Presents Vaccine Platform Data in Keynote Talk At the Vaccine Congress 2024

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.009881 million.

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500

ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $4.4 million.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society (Acs) Spring 2024 Meeting

Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy

Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers

Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD

Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of Tnx-102 Sl in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity

Tonix Pharmaceuticals Holding Corp. Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder

National Institute of Allergy and Infectious Diseases Selects Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving Tnx-1500 (Fc-Modified Dimeric Anti-Cd40l Mab) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. Announces Poster Presentation Showing Research Results for mTNX-1700

Tonix Pharmaceuticals Holding Corp. Announces Commitment to Supply Tosymra®? (Sumatriptan Nasal Spray) 10 Mg for Treatment of Acute Migraine

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Prevail Proof-Of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID

Tonix Pharmaceuticals Holding Corp. Announces Results of Pre-Ind Meeting with FDA for TNX-801 as A Potential Vaccine to Protect Against Mpox and Smallpox

Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-Modified Humanized Anti-Cd40l Mab) in Healthy Volunteers

Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia

Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder

Tonix Pharmaceuticals Holding Corp. Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023

Tonix Pharmaceuticals Holding Corp. Announces Data Supporting Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, But Not (R)-Tianeptine, in Vivo Rat Novel Object Recognition Test

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘Power’ Study of TNX-1900 Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) and Tonix Medicines, Inc. entered into an agreement to acquire Certain Assets of Upsher Smith Laboratories, LLC for $25 million.

Tonix Pharmaceuticals Holding Corp. Announces Publication of Results from Phase 3 RELIEF Trial of TNX 102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces Data Presentations Involving TNX-1500 (Anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models At the 2023 American Transplant Congress

Tonix Pharmaceuticals Holding Corp. Announces the Presentation of Data Detailing the Mechanism of Action and Pharmacokinetics of TNX-601 ER